Not known Factual Statements About semaglutide Week 1-6 Bundle
The trial reached the two its Major endpoints, with semaglutide 2.four mg demonstrating statistically major and outstanding improvements in liver fibrosis with no worsening of steatohepatitis, together with resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH when compared with placebo.1Inactive ingredients: